Stockscreener 앱 받기
19.51
0.31%
-0.06
시간 외 거래:
18.55
-0.96
-4.92%
전일 마감가:
$19.57
열려 있는:
$19.21
하루 거래량:
1.73M
Relative Volume:
2.53
시가총액:
$1.91B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+7.32%
1개월 성능:
-30.37%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$18.64
$22.57
1주일 범위
$15.95
$22.57
52주 변동 폭
$12.30
$32.81
Metsera Inc Stock (MTSR) Company Profile
명칭
Metsera Inc
전화
(212) 784-6595
주소
3 WORLD TRADE CENTER, NEW YORK
MTSR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
19.51 | 1.91B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-25 | 개시 | BofA Securities | Buy |
| 2025-02-25 | 개시 | Evercore ISI | Outperform |
| 2025-02-25 | 개시 | Guggenheim | Buy |
Metsera Inc 주식(MTSR)의 최신 뉴스
Lilly stock up rallying Structure and Metsera (GPCR:NASDAQ) - Seeking Alpha
Viking, Structure, Metsera on a tear as Pfizer drops obesity pill - MSN
Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha
Metsera plunges 44% after InvestingPro’s overvaluation warning By Investing.com - Investing.com South Africa
Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025 - Endpoints News
Metsera sees cash runway into 2027 - TipRanks
Metsera reports Q4 EPS ($3.52) vs. (94c) last year - TipRanks
Decoding Metsera Inc (MTSR): A Strategic SWOT Insight - GuruFocus
Are Metsera Inc’shares a good deal? - US Post News
Metsera's Q4 Net Loss Widens, Operating Expenses Rise; Shares Higher - marketscreener.com
Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio Progress - Marketscreener.com
Form 10-K Metsera, Inc. For: Dec 31 - StreetInsider
Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M - Marketscreener.com
Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share - MarketScreener
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress - The Manila Times
Metsera Inc (NASDAQ: MTSR) Stock Is Down -21.4% From Its Low: The Uptrend Is Still On - Stocks Register
Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com
IHS Holding Posts Upbeat Earnings, Joins Tencent Music Entertainment, Elbit Systems And Other Big Stocks Moving Higher On TuesdayDiginex (NASDAQ:DGNX), China Liberal Education (NASDAQ:CLEU) - Benzinga
Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Metsera, Inc. awards full bonuses to executive officers By Investing.com - Investing.com Australia
Metsera, Inc. awards full bonuses to executive officers - Investing.com India
Metsera, Inc. Approves 2024 Executive Cash Bonuses - TipRanks
Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
Why MicroStrategy Incorporated (MSTR) Soared on Tuesday - MSN
Metsera, Inc.’s Quiet Period To Expire on March 12th (NASDAQ:MTSR) - Defense World
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing - NewsBreak
Why Did Metsera Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing - Benzinga
Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
AbbVie Buys Into Obesity With Gubra Deal, While Novo Partners With Gensaic - insights.citeline.com
10 Best Weight Loss Drug Stocks to Buy According to Analysts - Insider Monkey
CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases - ACCESS Newswire
Metsera to Present at TD Cowen's 45th Annual Health Care Conference - The Manila Times
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference - The Bakersfield Californian
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation - Seeking Alpha
Metsera (NASDAQ:MTSR) Now Covered by Bank of America - Defense World
Metsera (NASDAQ:MTSR) Now Covered by Analysts at Evercore ISI - Defense World
Metsera started by Guggenheim at buy on obesity drug opportunity - MSN
Wall Street bullish on Metsera following January IPO on obesity drug pipeline - Investing.com Canada
Metsera started at buy at Guggenheim on obesity treatment potential - MSN
Why this newly public biotech could become a force in obesity treatments - MarketWatch
90% upside? This weight-loss drug play is worth a look - Invezz
This weight-loss drug stock could deliver a 90% return in 2025 - TradingView
Cantor Fitzgerald initiates Metsera with overweight rating - Investing.com India
Metsera Inc (MTSR) 재무 분석
Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.15%
4.32%
자본화:
|
볼륨(24시간):